Schistosoma mansoni Specific Neutra™ Antibody Products
Product listAccelerate Your Research and Development!
Are you currently facing challenges in diagnosing low-intensity S. mansoni infections, identifying novel vaccine candidates, or developing robust serological assays? Our S. mansoni Specific Neutra™ Antibody Products help you accelerate the discovery of crucial parasite antigens and refine diagnostic tool sensitivity through highly specific, well-characterized recombinant antibodies targeting key lifecycle proteins.
Contact our team to get an inquiry now!
Introduction of S. mansoni
Schistosoma mansoni is the parasitic flatworm responsible for intestinal schistosomiasis, a neglected tropical disease affecting over 200 million people globally, primarily across Africa and the Americas. The parasite cycle involves freshwater Biomphalaria snails (intermediate hosts) and mammals, including humans (definitive hosts). Pathology is caused not by the adult worms, which reside in the mesenteric venules, but by the hundreds of eggs they produce daily. When eggs become trapped in host tissues (liver/intestines), they secrete Soluble Egg Antigens (SEAs) which trigger granuloma formation, leading to severe periportal fibrosis and portal hypertension. Key antibody targets for research, drug screening, and vaccine development include Sm-p80, Sm-TSP-2 (a tegument protein), and Sm-Cathepsin B (Sm-CatB), as these are critical for parasite survival and immune modulation.
Fig.1 Life cycle of S. mansoni.1
Antibodies Against S. mansoni
Antibodies against S. mansoni antigens are indispensable reagents for research and public health, offering high-resolution analysis beyond low-sensitivity methods like Kato-Katz.
Applications of Anti-S. mansoni Antibodies:
- IHC/IF (Localization): High-specificity antibodies visualize target protein location (e.g., Sm-TSP-2, Sm-CatB) across life stages (cercaria, adult worm, egg). This confirms accessibility on the tegument, informing vaccine and functional studies.
- Antigen Detection in Diagnostics: Antibodies capture circulating antigens (CCA, CAA) in serum or urine, forming the basis of rapid, high-sensitivity immunoassays. This is vital for low-intensity infections where egg output is scarce.
- Western Blot/ELISA/LFA Development: Our Neutra™ antibodies confirm protein size (Western Blot) and are crucial for coating or detection in custom ELISA and Lateral Flow Assay (LFA) development, supporting epidemiological surveillance and treatment monitoring.
- Functional Blockade Studies: Research-grade antibodies determine if neutralizing a specific antigen (in vitro/in vivo) inhibits parasite development or damages the worm's surface, providing critical insights into drug action or vaccine-induced protection mechanisms.
Why Choose Us?
Creative Biolabs has provided superior, tailored tools for neglected tropical disease research.
- Exceptional Specificity: Neutra™ antibodies are meticulously engineered to ensure low cross-reactivity, minimizing false positives in sensitive diagnostic applications.
- High Batch-to-Batch Consistency: We guarantee superior reproducibility, essential for standardizing diagnostic assays and long-term clinical studies.
- Comprehensive Target Coverage: We offer an extensive portfolio covering key vaccine and diagnostic markers (Sm-TSP-2, CCA), ensuring you have access to the most impactful tools.
- Demonstrated Performance: Our antibodies are validated for performance across critical immunoassays (ELISA, IHC, WB), providing seamless integration into your research workflows. Supporting evidence is available.
FAQs
Q: Can these specific parasite antibodies be used to detect early-stage infections?
A: Yes. Antigen-based detection assays utilizing these antibodies target circulating parasite antigens, providing an earlier diagnostic window than traditional egg-based microscopy, which is crucial for prompt intervention.
Q: How reliable are antibody-based assays compared to DNA-based (PCR) methods for low-intensity infection screening?
A: Antibody-based antigen detection (like CCA LFAs/ELISA) offers excellent sensitivity, high-throughput, and cost-effectiveness for population screening. While PCR is extremely sensitive for DNA, antigen detection is simpler for field use and detects active infections efficiently. Both are powerful, complementary approaches.
Q: What is the optimal sample type?
A: The optimal sample type depends on the target antigen. Urine (for CCA/CAA) or serum samples are preferred for detecting circulating antigens due to ease of collection and high concentration.
Q: Do these antibodies show cross-reactivity with other helminth infections?
A: Our products are rigorously tested against panels of cross-reactive antigens to minimize non-specific binding. We recommend consulting technical specifications and using appropriate blocking strategies in co-endemic regions.
Q: Are these antibodies suitable for high-volume public health surveillance programs?
A: Absolutely. Our manufacturing ensures large-scale production with stringent QC, making them suitable for commercial diagnostic kits (LFTs and ELISA) used for mass drug administration (MDA) monitoring and epidemiological mapping.
Creative Biolabs supplies the highest quality S. mansoni Neutra™ Antibody Products, providing essential tools for schistosomiasis research—from pathogenesis and parasite biology to developing next-generation diagnostic and prophylactic solutions. Leverage our expertise for unprecedented specificity and consistency.
Access the Creative Biolabs Edge – Request Your Quote Now
REFERENCE
- Cleenewerk, L et al. "Clinical Use of Schistosoma mansoni Antigens as Novel Immunotherapies for Autoimmune Disorders." Frontiers in immunology vol. 11 1821. 13 Aug. 2020, Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3389/fimmu.2020.01821
